News October 2023

Recent Evidence Shows Clinical Utility of MolecuLight Point-of-Care Imaging Platform

MolecuLight Inc. recently announced the presentation of 6 clinical posters, a presentation, and a hands-on workshop at the American Professional Wound Care Association’s (APWCA) Wound Week^™ that showed clinical benefits to its imaging platform.

The 6 posters featuring the MolecuLight i:X were as follows:

Posters by Alisha Oropallo, MD, include:

• 12-week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates
• Pseudomonas Scrub Down: Advances in Wound Imaging Objectively Confirm the Efficacy of Acetic Acid Against this Pathogen

Posters by Charles Andersen, MD, include:

• Bacterial load imaging of chronic wound bacteria supports patient adherence, empowerment and may prevent negative outcomes
• Strategies to improve equity in wound bacterial-infection assessments on skin of color
• Multimodal imaging device for real-time bacterial load and thermal imaging: a study of synergy in clinical wound assessment workflow

Posters by Thomas Serena, MD, include:

• Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging

Click here for more info.

Mallinckrodt Receives FDA Label Update for First-of-Kind Burn Treatment for DPT Burns

Mallinckrodt recently announced it received an important label update from the Food and Drug Administration (FDA) for StrataGraft^®, a treatment for patients with deep partial-thickness (DPT) burns. The company says its first-of-its-kind technology supports the body’s own ability to heal without harvesting—as it does not permanently engraft and is replaced by the patient’s own cells over time.

Mallinckrodt says the StrataGraft label update reflects the FDA's acknowledgement of reduced xenotransplantation restrictions allowing recipients who otherwise meet donor requirements to be eligible to donate human cells, tissues, cellular or tissue-based products, human milk, ova, sperm, or organs for transplantation. In addition, the company says the FDA has waived its requirement to collect patient information and blood samples and to maintain a patient database, which alleviates the patient burden of additional testing.

Click here for more info.